Obinutuzumab is prescribed to treat chronic lymphocytic leukemia (CLL) in combination with chlorambucil in adult patients who have not been previously treated for CLL. Obinutuzumab in combination with bendamustine is used to treat follicular lymphoma (FL) followed by obinutuzumab monotherapy in patients whose cancer condition has returned or not responded to other cancer treating medications.<\/p>\n
FDA approved Gazyva (obinutuzumab), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).<\/p>\n
On 19 June 2015, orphan designation (EU\/3\/15\/1504) was granted by the European Commission to Roche Registration Limited, United Kingdom, for obinutuzumab for the treatment of follicular lymphoma. Obinutuzumab for treatment of follicular lymphoma has been authorised in the EU as Gazyvaro since 13 June 2016.<\/p>\n
If obinutuzumab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Approval Date: 2013 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cobinutuzumab injection\u201d based on the information you provide.<\/p>\n
\nProprietary Name: On Request
\nActive Ingredient(s): obinutuzumab
\nDosage Forms And Strengths: 1000 mg\/40 mL (25 mg\/mL) single-dose vial.
\nCompany: Roche
\nCurrent indications: chronic lymphocytic leukemia; follicular lymphoma
\nMedicine Approved By: \u2013<\/strong> European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA approved use on approval date:<\/strong> Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n